a public good project by the
Synthesis
Company
of California

© 2026

Michèle Tameris | doi.page

0 works0 citations0 h-index

Michèle Tameris

University of Cape Town(ZA)South African Tuberculosis Vaccine Initiative(ZA)

Publications by Year

Research Areas

Tuberculosis Research and Epidemiology, Mycobacterium research and diagnosis, Immunodeficiency and Autoimmune Disorders, Immune responses and vaccinations, Pneumonia and Respiratory Infections

Most-Cited Works

→ Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial(2013)1,027 cited
→ Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant(2021)657 cited
→ Final Analysis of a Trial of M72/AS01 _E Vaccine to Prevent Tuberculosis(2019)569 cited
→ Phase 2b Controlled Trial of M72/AS01 _E Vaccine to Prevent Tuberculosis(2018)397 cited
→ T-cell activation is an immune correlate of risk in BCG vaccinated infants(2016)268 cited
→ The Novel Tuberculosis Vaccine, AERAS-402, Induces Robust and Polyfunctional CD4+ and CD8+ T Cells in Adults(2010)227 cited

→ First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults(2015)

191 cited

→ Modified vaccinia Ankara‐expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells(2009)189 cited

→ Safety and Immunogenicity of a New Tuberculosis Vaccine, MVA85A, in Healthy Adults in South Africa(2008)169 cited

→ RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response(2020)165 cited